Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01271803 · ClinicalTrials.gov registry record · Phase 1
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
A Phase 1 study of Malignant Melanoma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 131
- Enrollment target
- 10
- Study locations
NCT01271803 is a Phase 1 study of Malignant Melanoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 131 participants, below the 179-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (27% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT01271803, a Phase 1 study of Malignant Melanoma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 131 participants
- Enrollment target
- 10
- Study locations
Study Summary
This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma. Participants with previously untreated, BRAFV600E mutation-positive, locally advanced/unresectable or metastatic melanoma or those who have progressed on vemurafenib monotherapy immediately prior to enrolling in this trial are eligible. Participants will be assigned to different cohorts with escalating oral doses of vemurafenib and cobimetinib. This study consists of 2 stages, Stage 1 (Dose Escalation Stage \[DES\] and Cohort Expansion Stage \[CES\]) and the anticipated time on study treatment is until disease progression, unacceptable toxicity or any other discontinuation criterion is met.
Conditions Studied
Interventions
- DRUG Cobimetinib
- DRUG vemurafenib
Study Locations (10)
California
- UCLA Department of Medicine - Los Angeles
- University of California at San Francisco - San Francisco
- The Angeles Clinic and Research Institute, Santa Monica Office - Santa Monica
Colorado
- University of Colorado; Anschutz Cancer Pavilion - Aurora
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Department of Medicine, Division of Gastroenterology/Hepatology - Indianapolis
Michigan
- Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building - Detroit
New York
- New York University Medical Center - New York
Tennessee
- Vanderbilt University Medical Center - Nashville
Victoria
- Peter Maccallum Cancer Institute; Medical Oncology - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2011-02-17 |
| Est. Completion | 2017-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01271803
The ClinicalTrials.gov registry entry for NCT01271803 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (27% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Cobimetinib is the first listed.
NCT01271803 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT01271803 about?
NCT01271803 is a clinical study titled "A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma". This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma. Participants with previously untreated, BRAFV600E mutation-positive, locally advanced...
What is the current status of trial NCT01271803?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 131 participants. The study started on 2011-02-17. Estimated completion is 2017-12-12.
What conditions does trial NCT01271803 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT01271803?
The interventions under investigation include: Cobimetinib (DRUG), vemurafenib (DRUG).
Who is sponsoring clinical trial NCT01271803?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01271803 being conducted?
This trial has 10 study locations across California, Colorado, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.